CFO — Scott Gleason: The filing announces the appointment of an external candidate as the new CFO and Treasurer, which is a significant management change but not a departure of a sitting executive.

Results of Operations and Financial Condition. On August 12, 2026, Sera Prognostics, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2026 and providing business highlights. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 19…

Class II director and member of the Compensation Committee — Mark Capone: Appointment of Mark Capone as a Class II director and member of the Compensation Committee.

Director — Jeffrey T. Elliott: Mr. Elliott resigned from the Board of Directors, and his term was not renewed at the Annual Meeting.

Results of Operations and Financial Condition. On May 6, 2026, Sera Prognostics, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2026 and providing business highlights. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,…

Results of Operations and Financial Condition. On March 18, 2026, Sera Prognostics, Inc. issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2025 and providing business highlights. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities…

Results of Operations and Financial Condition. On November 13, 2025, Sera Prognostics, Inc. issued a press release announcing its financial results for the third quarter ended September 30, 2025 and providing business highlights. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act…

Results of Operations and Financial Condition. On August 6, 2025, Sera Prognostics, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2025 and providing business highlights. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 193…

Results of Operations and Financial Condition. On May 7, 2025, Sera Prognostics, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2025 and providing business highlights. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,…

Results of Operations and Financial Condition. On March 19, 2025, Sera Prognostics, Inc. issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2024 and providing business highlights. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities…

Entry into a Material Definitive Agreement. On February 10, 2025, Sera Prognostics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC and William Blair & Company, L.L.C., as representatives of the several underwriters named therein (the “Underwriters”), relating to the issuance and sale in an underwritten public offering (the “Offering”) by the Company of 1,250,000 shares of Class A common stock, par value $0…

Other Events. Termination of “At-the-Market” Offering Prospectus Supplement Pursuant to that certain sales agreement, dated August 7, 2024 (the “Sales Agreement”), that Sera Prognostics, Inc. (the “Company”) entered into with TD Securities (USA) LLC (“TD Cowen”), the Company may offer and sell, from time to time, shares of its Class A common stock, par value $0.0001 per share (the “Class A Common Stock”) through TD Cowen, acting as agent, through an “at the market offering” as defined in Rule…

Other Information. Presentation of PRIME Study Results Overview On January 31, 2025, final results of the Company’s PRIME study were presented at the Society for Maternal Fetal Medicine (“SMFM”) 2025 Pregnancy Meeting, and will again be presented at a subsequent virtual R&D day session hosted by the Company and the principal investigator. The study achieved both of its co-primary endpoints, showing significant reductions in the neonatal morbidity and neonatal hospital stays among low-risk pat…

Results of Operations and Financial Condition. Estimated Cash Balance as of December 31, 2024 (unaudited) Sera Prognostics, Inc. (the “Company”) is providing the following financial information. As of December 31, 2024, the Company’s cash, cash equivalents and marketable securities were approximately $68.2 million (unaudited). The estimated cash, cash equivalents and marketable securities as of December 31, 2024 are preliminary and may change, and are based on information available to managem…

Results of Operations and Financial Condition. On November 6, 2024, Sera Prognostics, Inc. issued a press release announcing its financial results for the third quarter ended September 30, 2024 and providing business highlights. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act…

Results of Operations and Financial Condition. On August 7, 2024, Sera Prognostics, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2024 and providing business highlights. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 193…

Results of Operations and Financial Condition. On May 8, 2024, Sera Prognostics, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2024 and providing business highlights. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,…

and Item 7.01, including Exhibit 99.1 and Exhibit 99.2 furnished herewith, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that section, nor shall it be deemed incorporated by reference in any registration statement or other document pursuant to the Securities Act of 1933, as amended, or into any filing or other document pursuant to the Exchange Act, except to th…

Entry into a Material Definitive Agreement. On December 6, 2023, Sera Prognostics, Inc. (the “Company”) entered into the second amendment (“Amendment No. 2”) to that certain Side Letter, dated as of April 29, 2021 (the “Side Letter”), previously amended effective February 16, 2023, with Baker Bros. Advisors LP and certain affiliates of Baker Bros. Advisors LP (collectively, “Baker Bros. Investors”). Pursuant to Amendment No. 2, the Baker Bros. Investors’ right to nominate one director to the…

Results of Operations and Financial Condition. On November 8, 2023, Sera Prognostics, Inc. issued a press release announcing its financial results for the third quarter ended September 30, 2023 and providing business highlights. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act…

Results of Operations and Financial Condition. On August 9, 2023, Sera Prognostics, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2023 and providing business highlights. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 193…

Chief Medical Officer — Michael R. Foley, M.D.: Dr. Foley resigned from his position as Chief Medical Officer and moved to a consulting role.

Chief Financial Officer — Jay Moyes: Mr. Moyes resigned from the position of Treasurer and Chief Financial Officer.

President and Chief Executive Officer of the Company and Chairman of the Board of Directors — Gregory C. Critchfield, M.D., M.S.: Dr. Gregory C. Critchfield retired from his positions with a severance package and forfeiture of unvested equity awards.

President and Chief Executive Officer and Chairman of the Board of Directors — Gregory C. Critchfield, M.D., M.S.: Dr. Gregory C. Critchfield is retiring from his executive positions but will continue as a board member, with Zhenya Lindgardt appointed as Interim CEO.